

Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests

Name of Advisory Committee Member: **David Harrington, Ph.D.**


Committee: Oncologic Drug Advisory Committee

Meeting Date: March 31, 2009

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: to discuss the supplemental biologic license application (sBLA) 125085/169, trade name Avastin (bevacizumab), proposed indication as single agent, for the treatment of previously treated glioblastoma multiforme, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None	None	None
Imputed Interests		
<ul style="list-style-type: none"> <li>• Subcontract</li> <li>• Subcontract</li> <li>• Subcontract</li> <li>• Subcontract</li> <li>• Subcontract</li> </ul>	<ul style="list-style-type: none"> <li>• Sponsor</li> <li>• Sponsor</li> <li>• Sponsor</li> <li>• Sponsor</li> <li>• Sponsor</li> </ul>	<ul style="list-style-type: none"> <li>• \$0 – 50,000</li> <li>• Over \$300,000</li> <li>• Over \$300,000</li> <li>• \$0 – 50,000</li> <li>• \$0 – 50,000</li> </ul>

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.



\_\_\_\_\_  
Signature

March 26, 2009  
Date